Therefore, targeting specific CD4+ and/or CD8+ T cell populations could offer potential therapeutic strategies to modulate immune responses, attenuate inflammation, and mitigate atherosclerosis progression and associated cardiovascular risks [11]. Here, CD4 is linked to atherosclerosis.